OVID (Ovid Therapeutics Inc. Common Stock) Stock Analysis - Politician Trades

Ovid Therapeutics Inc. Common Stock (OVID) is a publicly traded Healthcare sector company. As of May 21, 2026, OVID trades at $2.42 with a market cap of $449.80M and a P/E ratio of 0.00. OVID moved -0.42% today. Year to date, OVID is +43.98%; over the trailing twelve months it is +724.71%. Its 52-week range spans $0.24 to $3.11. Analyst consensus is strong buy with an average price target of $5.33. Rallies surfaces OVID's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded OVID stock?

Rallies tracks politician and congressional stock disclosures for OVID, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

OVID Key Metrics

Key financial metrics for OVID
MetricValue
Price$2.42
Market Cap$449.80M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$3.11
52-Week Low$0.24
Volume20
Avg Volume0
Revenue (TTM)$7.12M
Net Income$-24.17M
Gross Margin0.00%

Latest OVID News

Recent OVID Insider Trades

  • ALEXANDER MARGARET A. sold 11.66K (~$16.90K) on Feb 23, 2026.
  • Rona Jeffrey A sold 8.54K (~$12.38K) on Feb 23, 2026.
  • ALEXANDER MARGARET A. sold 5.28K (~$2.96K) on Feb 26, 2025.

OVID Analyst Consensus

8 analysts cover OVID: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.33.

Common questions about OVID

Which politicians traded OVID stock?
Rallies tracks politician and congressional stock disclosures for OVID, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in OVID?
Yes. Rallies tracks politician and congressional stock disclosures for OVID, including reported purchases, sales, dates, owners, and trade amounts when available.
Is OVID research on Rallies investment advice?
No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.
OVID

OVID